Healthcare Belgian Community
Our community narratives are driven by numbers and valuation.
Healthcare Belgian Investing Ideas
Agfa-Gevaert is a digital and materials turnaround opportunity, with growth potential in ZIRFON, but carrying legacy risks.
Agfa-Gevaert is trying to turn itself from a fading film business into a focused company built around hospital imaging software, industrial printers, and new materials used in clean-energy equipment. The upside comes from newer products gaining traction, but the company still has to manage old liabilities and the slow decline of its legacy film activities.Read more
Clinic And Home Neuromodulation Adoption Will Drive Long Term Opportunity
Onward Medical is betting that more rehab clinics adopt its ARC-EX therapy and that patients eventually use it at home, turning early interest into steadier, repeat use. The upside depends on insurance coverage and trial results for a second use case, while cash burn and changing healthcare rules could slow the rollout.Read more
APAC Expansion And Compounding Services Will Unlock Future Value
Fagron is pushing into new regions and leaning into made-to-order medicines as hospitals and pharmacies look for more flexible options amid drug shortages and an aging population. The big question is whether its growth plan and upgrades in automation can outweigh supply chain, regulatory, and currency bumps along the way.Read more
FDA Approval And Expanding Network Will Grow US Sleep Market
Nyxoah is bringing a new implant option for sleep apnea to the U.S. after a key health regulator green light, and early signs suggest doctors and treatment centers are gearing up to offer it. The upside is wider insurance coverage and expanded use over time, but competition, legal fights, and heavy spending could slow the rollout.Read more
Minimally Invasive Devices Will Capture Expanding Sleep Market
A new sleep apnea implant from Nyxoah could appeal to more patients and doctors than today’s options, helping it break into the large U.S. market faster than many expect. But the story hinges on one device and a chain of approvals and insurance decisions that could slow adoption and keep losses going longer.Read more
Regulatory Delays Will Hinder Revenue Ramp But Allow Recovery
Key Takeaways Regulatory, reimbursement, and administrative hurdles in the U.S. could restrict revenue growth, delay account expansion, and compress margins despite strong market demand. Innovation pressures, rising R&D costs, and increased competition threaten long-term profitability, market share, and Genio's premium product positioning.Read more
Neurostimulation Adoption And Brain Computer Interfaces Will Transform Long Term Prospects
Catalysts About Onward Medical Onward Medical develops neurostimulation therapies aimed at improving function and quality of life for people with spinal cord injury and related movement disabilities. What are the underlying business or industry changes driving this perspective?Read more
Challenged Reimbursement And Cash Burn Will Test Neurostimulation Thesis Yet Long Term Potential Remains
Catalysts About Onward Medical Onward Medical develops and commercializes neurostimulation systems intended to improve function and quality of life for people with spinal cord injury. What are the underlying business or industry changes driving this perspective?Read more
Proton Therapy Expansion Will Transform Global Cancer Treatment
Key Takeaways Sustained demand for advanced proton therapy and expansion into new markets are driving long-term revenue growth and improved earnings visibility. Continued R&D investments and growth in service contracts are enhancing margins, competitive positioning, and recurring high-margin revenue streams.Read more
